Drugs / NOX66
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05100628 | Feb 2022 → May 2023 | soft tissue sarcoma | Noxopharm Limited | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04555213 | Sep 2020 → Aug 2021 | COVID-19 | Noxopharm Limited | Completed | No outcome recorded |
| Phase 1 | NCT03307629 | Nov 2017 → Dec 2019 | cancer | Noxopharm Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02941523 | Mar 2017 → Dec 2018 | cancer | Noxopharm Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 27
| Date | Issuer | Release |
|---|---|---|
| 2023-05-26 | Noxopharm Limited | Results IONIC Trial Abstract Published at ASCO noxopharm.com ↗
Sydney, 26 May 2023: Innovative biotech company Noxopharm Limited (ASX:NOX) announces preliminary data from the IONIC investigator-initiated pilot Phase 1 trial of oncology drug candidate Veyonda® has been published online in the form of an abstract at the American Society of Clinical Oncology (ASCO) annual meeting taking place in Chicago from 2-6 June 2023. |
| 2021-03-05 | Noxopharm Limited | Results Noxopharm Presents to H.C. Wainwright Global Conference noxopharm.com ↗
Median Overall Survival: 19.7 monthsa remarkable result for this late stage of the disease |
| 2021-02-15 | Noxopharm Limited | Results LuPIN Survival Outcome Confirmed by Conference Presentation noxopharm.com ↗
Drug combination NOX66 (Veyonda) and 177lutetium-PSMA-617 delivers high response rates in heavily pre-treated men with end-stage prostate cancer |
| 2021-02-09 | Noxopharm Limited | Results Major Survival Benefit in Prostate Cancer Patients Announced noxopharm.com ↗
Today’s clinical data continues to cement the view that Veyonda (NOX66) is on track to become a major new immunotherapy oncology drug of medical and commercial significance. |
| 2020-06-01 | Noxopharm Limited | Results ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer noxopharm.com ↗
Noxopharm (ASX: NOX) today reports on the public release at a global oncology conference of 2 sets of clinical data relating to the development of NOX66 (Veyonda®) as a treatment of end-stage cancer. |
| 2020-05-19 | Noxopharm Limited | Regulatory FDA allows Veyonda Pre-IND Submission for COVID-19 noxopharm.com ↗
Noxopharm (ASX:NOX) today announces that on advice from the U.S. Food and Drug Administration (FDA), the Company has lodged a pre-Investigational New Drug (pre-IND) submission for a clinical trial of Veyonda® in patients with SARS-CoV-2 (COVID-19) infection. |
| 2020-05-14 | Noxopharm Limited | Results Noxopharm ASCO Abstracts Live noxopharm.com ↗
Noxopharm (ASX: NOX) today announces the publication by The American Society of Clinical Oncology (ASCO) of three abstracts concerning Veyonda® ahead of the Society’s virtual 2020 Annual Meeting from 29 to 31 May 2020. |
| 2020-04-30 | Noxopharm Limited | Results Abscopal Responses Achieved in Prostate Cancer noxopharm.com ↗
Noxopharm (ASX:NOX) today releases details of the radiographic review of its DARRT-1 clinical study and is pleased to report that it shows a major benefit from a combination of Veyonda® and low-dose radiotherapy. |
| 2020-01-29 | Noxopharm Limited | Results Noxopharm Non-Deal Roadshow Presentation noxopharm.com ↗
In summary, combination therapy of Veyonda® and 177Lu-PSMA-617 shows benefits to patients well above that achieved with 177Lu-PSMA-617 therapy alone and underscores the Company’s confidence in Veyonda® eventually becoming a standard drug in the management of prostate cancer |
| 2019-12-02 | Noxopharm Limited | Results Positive DARRT-1 Data in Late-Stage Prostate Cancer noxopharm.com ↗
This is exciting data that validates our confidence in the future of the NOX66 DARRT treatment regimen. |
| 2019-11-12 | Noxopharm Limited | Results DARRT-1 Interim Data Presented To Conference noxopharm.com ↗
6/14 (43%) experienced a pain response (>30% reduction in pain) including 2 who were pain-free |
| 2019-11-12 | Noxopharm Limited | Results LuPIN Data Being Presented To Conference noxopharm.com ↗
Within the limits of comparing data sets from different studies, combination therapy was superior to monotherapy in terms of: |
| 2019-10-30 | Noxopharm Limited | Results Noxopharm October 2019 Newsletter noxopharm.com ↗
The leading article comments on the interim data from the DARRT-1 clinical study showing that a combination of Veyonda and low -dose radiotherapy is stopping the growth of late -stage prostate cancer and providing durable pain relief in a high proportion of men. |
| 2019-09-30 | Noxopharm Limited | Results Further Review Shows Major Clinical Benefits from Veyonda noxopharm.com ↗ |
| 2019-06-26 | Noxopharm Limited | Results Conference Hears of Positive Interim Data from LuPIN Trial noxopharm.com ↗
Clinical data shows combining Veyonda with radiopharmaceutical, 177Lu-PSMA-617, is well tolerated and with early signals of anti-cancer activity |
| 2019-05-20 | Noxopharm Limited | Results LuPIN Trial Demonstrates High Rates of Response noxopharm.com ↗
75% of men treated with Veyonda 800 mg and 177Lu-PSMA-617 achieved a PSA response. |
| 2019-05-02 | Noxopharm Limited | Results DARRT Treatment Has Lasting Disease Control at Six Months noxopharm.com ↗ |
| 2019-02-06 | Noxopharm Limited | Results Veyonda and Radiotherapy Delivers Clinical Benefits noxopharm.com ↗
combining Veyonda with low-dose radiotherapy applied to a single metastasis (lesion) is able to produce an anti-cancer response in both the irradiated and non-irradiated lesions as evidenced by PSA response, pain reduction, and/or tumour measurements |
| 2018-11-29 | Noxopharm Limited | Results NOX announces Positive Data from CEP-1 Study of Veyonda noxopharm.com ↗
Noxopharm (ASX: NOX) announces the final results from its Phase 1b CEP-1 trial evaluating its lead immuno-oncology/radio-enhancer drug candidate, Veyonda, in combination with low-dose carboplatin in late-stage metastatic solid cancers. |
| 2018-08-08 | Noxopharm Limited | Results Interim NOX66 Radiotherapy Clinical Data noxopharm.com ↗
DARRT-1 provides evidence of more abscopal responses |
| 2018-07-09 | Noxopharm Limited | Results Release of DARRT-1 Preliminary Safety Data noxopharm.com ↗
The data reported today is from 9 patients (8 patients in Cohorts 1 and 2; one patient in Cohort 3). |
| 2018-07-05 | Noxopharm Limited | Results Pre-Clinical data confirms Radio-Enhancing potential noxopharm.com ↗
Idronoxil was able to kill these cancer cells on its own, but more importantly, sensitised the cells to radiation, leading to a significantly higher level of death of cancer cells using a constant dosage of radiation. |
| 2018-06-05 | Noxopharm Limited | Results End-of-Study Clinical Data shows benefit of NOX66 noxopharm.com ↗
Sydney, 5 June 2018: Noxopharm (ASX: NOX) today presented key end -of-study clinical data from its Phase 1b CEP-1 clinical study to the 2018 Annual Meeting of American Society of Clinical Oncology in Chicago, USA. |
| 2018-05-22 | Noxopharm Limited | Results NOX to present at American Society of Clinical Oncology noxopharm.com ↗
In the meantime, we have conducted sufficient analysis to be able to report here that the study has finish ed with no reports of serious adverse events being attributed to NOX66 . |
| 2018-04-17 | Noxopharm Limited | Results St Vincent's Hospital study passes first milestone noxopharm.com ↗
We are encouraged to see good PSA responses in 3 of the first 4 men treated, particularly when we note that this is with a low dosage of NOX66. |
| 2018-03-21 | Noxopharm Limited | Results Evidence of Abscopal Responses in Patients noxopharm.com ↗
Abscopal responses obtained in both patients |
| 2018-03-06 | Noxopharm Limited | Results NOX Reports NOX66 Clinical Data noxopharm.com ↗
Disease progression blocked in the majority of patients (12/14) after 3 months |
All press releases naming this drug 29 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NOX66 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05100628 ↗ |
| Modality | Small molecule | “Idronoxil is a synthetic small molecule” NCT02941523 ↗ |
| Route | Rectal | “NOX66 delivered as rectal suppository.” NCT03307629 ↗ |